|Dr. Peter Wrighton-Smith||CEO & Exec. Director||669.26k||1.51M||1974|
|Mr. Stefan C. Linn||Chief Operating Officer||614k||N/A||1965|
|Mr. Matthew T.E. McLaughlin||Chief Financial Officer||N/A||N/A||1977|
|Ms. Karen C. Koski||VP of Strategy & Investor Relations||N/A||N/A||N/A|
|Dr. Peter Edwardson||Sr. VP & Head of Blood Screening||N/A||N/A||1962|
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. The company develops and markets T-SPOT.TB test used to test for tuberculosis. It is also developing C6 Borrelia burgdorferi (Lyme) ELISA kit, which measures Lyme specific antibodies; and T-SPOT.CMV test that utilizes its T-SPOT technology platform to measure the strength of a patient's cellular immune response to antigens specific to cytomegalovirus (CMV), as well as provides information for informing management strategies of patients at risk of CMV infection and disease, such as transplant patients. The company markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan, as well as through distributors internationally. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
Oxford Immunotec Global PLC’s ISS Governance QualityScore as of April 1, 2019 is 5. The pillar scores are Audit: 3; Board: 4; Shareholder Rights: 5; Compensation: 8.